Indeed, early studies in breast cancer cell lines showed IFN-β to be highly superior to IFN-α; accordingly, IFN-β was suggested for the treatment of all breast cancers, irrespective of their steroid receptor status [187]. This evidence concerns the gene IFNB1 and breast carcinoma.